Intracranial Hemorrhage The Culprit In Merck's Vorapaxar Trial
This article was originally published in The Pink Sheet Daily
Merck &Co. remains unsure about regulatory filing plans for the compound, while still waiting to see clinical trial data.
You may also be interested in...
FDA approves antiplatelet inhibitor with a label that makes little mention of the safety concerns seen in lightweight patients, despite a vibrant FDA and advisory panel discussion on how to present the unfavorable data, but the company still has a big marketing challenge ahead.
As the platelet inhibitor heads to an advisory committee, agency reviewers raise issues about safety-based changes to its Phase III trials.
Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.